OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

Rhea-AI Summary

OneMedNet (Nasdaq: ONMD) announced a collaboration with Onco-Innovations and its subsidiary Inka Health to provide access to OneMedNet’s iRWD™ platform, powered by Palantir Foundry, for U.S. oncology real-world data. The pilot focuses on accelerating development and evidence generation for Onco’s PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.

The agreement will support patient responder identification, indication expansion beyond metastatic colorectal cancer, and SynoGraph™ model development.

News Market Reaction – ONMD

-0.75%

8 alerts

-0.75% Session close to close

+3.9% Peak in 30 hr 58 min

$48.54M Market Cap

0.3x Rel. Volume

In the Apr 1 session, ONMD declined 0.75%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.9% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement deepens ONMD’s AI-driven oncology strategy by giving Onco-Innovations and Inka Hea...

Analysis

This announcement deepens ONMD’s AI-driven oncology strategy by giving Onco-Innovations and Inka Health access to its Palantir-powered iRWD platform and U.S. real-world oncology data. The focus on PTEN/SHP1-deficient tumors and causal-inference modeling with SynoGraph™ extends earlier AI collaborations. Investors may watch how this translates into new projects, regulatory-grade evidence use cases, and whether it builds on past AI news that previously saw an average 34.59% one-day move.

Previous AI Reports

5 past events · Latest: Jan 22 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 22	AI regulatory support	Positive	+12.1%	ONMD data backed FDA 510(k) clearance for AI BrainCT-ICH software.
Nov 10	AI platform launch	Positive	+4.7%	Unveiled Palantir-powered AI subscription RWD platform and tools.
Oct 06	Palantir AI deal	Positive	+148.5%	Multi-year Palantir AI agreement tied to large RWD network.
Jul 31	Oncology AI project	Positive	+3.8%	Inka-led AI oncology project using ONMD’s iRWD for ECAs.
Jul 30	Oncology AI project	Positive	+3.8%	Onco-Innovations detailed AI oncology collaboration with ONMD data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI‑tagged announcements for ONMD have consistently coincided with positive next‑day price moves.

Recent Company History

Across recent AI announcements, ONMD has highlighted Palantir‑powered analytics, large‑scale multimodal datasets, and applications in regulated AI tools and oncology research. Events such as the Jan 22, 2026 BrainCT‑ICH clearance support the platform’s regulatory credibility, while prior Inka collaborations showed oncology AI use cases. These AI news items have generally produced positive one‑day returns, framing today’s oncology‑focused AI collaboration as part of an ongoing strategy to monetize real‑world data in complex disease areas.

Key Terms

real-world data, ai-ready, real-world oncology data, pnkp inhibitor technology, +4 more

8 terms

real-world data medical

"accelerate Potential for Oncology Drug Development Using Real-World Data and AI"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

ai-ready technical

"a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD)"

AI-ready means that a company’s data, software and operations are organized and compliant so artificial intelligence tools can be added quickly and safely. Think of it like a house pre-wired for electricity: the infrastructure, quality of data and privacy safeguards are in place so AI can be switched on with lower cost, less delay and fewer regulatory surprises. For investors, AI-ready status often signals faster product rollouts, clearer conversion of data into value, and reduced implementation risk.

real-world oncology data medical

"providing it access to U.S. real-world oncology data"

Patient information collected outside controlled clinical trials about how cancer is diagnosed, treated and how patients actually fare in routine care settings. Like comparing a staged studio photo to candid street photos, this real-world evidence shows how therapies perform across diverse patients and everyday conditions, which matters to investors because it helps predict market demand, reimbursement chances, safety issues, and the likelihood a treatment will be widely adopted.

pnkp inhibitor technology medical

"Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers"

PNKP inhibitor technology is a class of drugs that block the PNKP enzyme, a cellular tool that helps fix damaged DNA; stopping that repair is like cutting off the maintenance crew so defects pile up and damaged cells are more likely to die. For investors, these molecules matter because they can make existing cancer therapies (like radiation or certain chemotherapies) work better or overcome resistance, so clinical trial results, safety profiles, and regulatory decisions can materially affect a developer’s valuation and market potential.

pten/shp1-deficient medical

"patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, —such as PTEN/SHP1-deficient tumors—"

Cells or tumors described as PTEN/SHP1-deficient lack normal function of two genes that act like cellular ‘brakes’ and ‘safety checks’ to control growth and immune signaling. For investors, this matters because such deficiencies often drive more aggressive disease and can change how well therapies work, making these tumors important targets for new drugs, biomarkers for clinical trials, and factors that influence a treatment’s commercial potential.

multimodal medical data medical

"by analyzing multimodal medical data"

Multimodal medical data is a mix of different kinds of patient information—such as X‑ray and MRI images, doctor notes, lab numbers, heart monitor traces, and genetic tests—combined to give a fuller picture of health. For investors, it matters because products that can join these “puzzle pieces” more accurately can improve diagnoses, support new AI tools, and create higher-value services that may drive adoption, revenue growth, and regulatory scrutiny.

causal-inference technical

"SynoGraph™, its causal-inference based AI platform that aims to predict"

Causal inference is the set of methods used to determine whether one action or event actually causes another, rather than merely occurring alongside it. For investors, it matters because it helps separate real drivers of outcomes—like whether a policy, marketing push, drug, or economic change will produce a measurable effect—from coincidences; think of it like comparing two nearly identical plants, one given fertilizer and one not, to see if growth was truly caused by the fertilizer.

regulatory decision-grade regulatory

"a leading provider of regulatory decision-grade, AI-ready Real-World Data"

Regulatory decision-grade describes data, studies, or documentation that meet the strict quality, completeness and reliability standards regulators require to decide whether a product is safe and effective. For investors, it signals that the evidence package is robust enough to support approvals or clearances—similar to having a thoroughly inspected blueprint before building—reducing uncertainty about whether a regulatory agency will accept the submission.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet’s iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.

Under the agreement, Inka Health is gaining access to OneMedNet’s iRWD™ platform through a selective pilot program following technical evaluation and qualification. The collaboration will initially focus on applying real-world data and advanced analytics to support Onco’s PNKP Inhibitor Technology’s development strategy, including patient responder identification, indication expansion beyond advanced metastatic colorectal cancer, and complementary evidence generation to inform clinical and regulatory decision-making. Inka Health also intends to use OneMedNet’s iRWD™ platform to improve and further develop the core model of SynoGraph™, its causal-inference based AI platform that aims to predict the success and safety of potential new cancer treatments by analyzing multimodal medical data.

Importantly, this engagement reflects the original architectural intent of the iRWD™ platform: to enable rapid identification and characterization of rare and molecularly defined patient populations at scale. By combining multi-modal data, longitudinal clinical context, and AI-augmented search capabilities, the platform is purpose-built to locate hard-to-find cohorts, —such as PTEN/SHP1-deficient tumors—, and accelerate innovation in areas where traditional trial recruitment and evidence development can be challenging.

“This collaboration demonstrates exactly what our iRWD™ platform was designed to do—find and characterize rare, high-value patient populations to accelerate innovation,” said Aaron Green, CEO & President of OneMedNet. “By bringing together regulatory-grade real-world data, multi-modal clinical depth, and Palantir-powered AI, we can help oncology innovators de-risk development, move faster, and generate meaningful evidence in complex disease segments.”

“Access to high-quality U.S. oncology real-world data is a critical enabler for PNKP Inhibitor Technology,” said Thomas O’Shaunghnessy, CEO of Onco-Innovations. “This collaboration allows us to better understand real-world patient populations with PTEN/SHP1-deficient tumors, identify potential responders, and explore additional indications—, helping us de-risk development while improving capital efficiency for shareholders.”

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”
Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055
investors@oncoinnovations.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements.  These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

FAQ

What did OneMedNet (ONMD) announce on April 1, 2026 about its iRWD platform access?

OneMedNet announced a collaboration granting Onco-Innovations/Inka Health pilot access to iRWD™ for U.S. oncology data. According to the company, the selective pilot follows technical evaluation and qualification and aims to apply RWD and analytics to support PNKP inhibitor development.

How will the OneMedNet-Onco collaboration affect development of Onco-Innovations' PNKP Inhibitor Technology?

The collaboration aims to accelerate development timelines and reduce clinical and regulatory risk for the PNKP program. According to the company, iRWD™ will help identify potential responders and support indication expansion beyond advanced metastatic colorectal cancer.

What role does Palantir Foundry play in OneMedNet's iRWD platform for ONMD collaboration?

Palantir Foundry powers the iRWD™ platform used in the collaboration to deliver AI-ready, multi-modal oncology data. According to the company, the Foundry-enabled platform enables AI-augmented search and characterization of rare molecular cohorts like PTEN/SHP1-deficient tumors.

How will Inka Health use OneMedNet's iRWD to develop its SynoGraph AI platform?

Inka Health intends to use iRWD™ to improve SynoGraph’s causal-inference core and predict treatment success and safety. According to the company, combining longitudinal multimodal data will help refine SynoGraph’s models for real-world responder identification and safety signals.